Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker study for YOTSUBA trial in advanced biliary tract cancer
jRCT1031240320Phase 3Recruiting
- Sponsor
- Kanagawa Prefectural Cancer Center
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in biliary cancer comparing Gemcitabine + cisplatin + S-1 with Gemcitabine + cisplatin + immune checkpoint inhibitor (2 arms). Primary endpoint: Overall survival prediction model. Started Aug 2024; status: recruiting.
02
Drugs
gemcitabinecisplatintegafur
03
Conditions
biliary cancer
Beyond the preview
Go deeper on jRCT1031240320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031240320.